Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-024-10764-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary: Pushing the envelope in Ebstein anomaly: Doing more with less.
J Thorac Cardiovasc Surg
November 2024
Department of Cardiothoracic Surgery, The Royal Children's Hospital, Melbourne, Victoria, Australia.
Viral coagulation: pushing the envelope.
J Thromb Haemost
December 2024
Centre for Blood Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Division of Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
Many virus types affect the blood clotting system with correlations to pathology that range widely from thrombosis to hemorrhage linking to inflammation. Here we overview the intricate crosstalk induced by infection between proteins on the virus encoded by either the host or virus genomes, coagulation proteins, platelets, leukocytes, and endothelial cells. For blood-borne viruses with an outer covering acquired from the host cell, the envelope, a key player may be the cell-derived trigger of coagulation on the virus surface, tissue factor (TF).
View Article and Find Full Text PDFPushing the envelope… who reaps the benefits?
J Vasc Surg
September 2024
NYU Langone Health/NYU Grossman School of Medicine, New York, NY.
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.
Expert Rev Hematol
October 2024
Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
Article Synopsis
- Bruton's tyrosine kinase inhibitors (BTKis), including zanubrutinib, revolutionized the treatment of chronic lymphocytic leukemia (CLL) but have various side effects that affect patient tolerability.* -
- The ALPINE trial demonstrated that zanubrutinib has superior clinical efficacy and progression-free survival compared to ibrutinib, with fewer cardiac toxicities but similar rates of neutropenia and hypertension.* -
- Zanubrutinib is emerging as a new standard treatment for relapsed/refractory CLL, and ongoing research is exploring advanced therapies and drug combinations to further improve patient outcomes.*
Development and Investigation of a Grasping Analysis System with Two-Axis Force Sensors at Each of the 16 Points on the Object Surface for a Hardware-Based FinRay-Type Soft Gripper.
Sensors (Basel)
July 2024
Department of Mechanical Engineering, Gifu University, Gifu 501-1193, Japan.
The FinRay soft gripper achieves passive enveloping grasping through its functional flexible structure, adapting to the contact configuration of the object to be grasped. However, variations in beam position and thickness lead to different behaviors, making it important to research the relationship between structure and force. Conventional research using FEM simulations has tested various virtual FinRay models but replicating phenomena such as buckling and slipping has been challenging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!